What is the recommended dosage of fluconazole (Diflucan) for treating candida infections?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 8, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Fluconazole Dosing for Candida Infections

For treating candida infections, fluconazole should be administered with a loading dose of 800 mg (12 mg/kg), followed by 400 mg (6 mg/kg) daily for most invasive infections, with specific adjustments based on infection site and severity. 1

Dosing Recommendations by Infection Type

Invasive Candidiasis/Candidemia

  • Initial therapy: Loading dose of 800 mg (12 mg/kg), then 400 mg (6 mg/kg) daily 1
  • Duration: At least 2 weeks after documented clearance of Candida from bloodstream 1
  • Alternative: For moderately severe to severe illness or recent azole exposure, consider an echinocandin instead 1

Oropharyngeal Candidiasis

  • Mild disease: 100-200 mg daily for 7-14 days 1
  • Moderate to severe disease: 200 mg on first day, then 100 mg daily for 7-14 days 2

Esophageal Candidiasis

  • Standard regimen: 200 mg on first day, followed by 100 mg daily 2
  • Severe cases: Doses up to 400 mg daily may be used 2
  • Duration: Minimum 3 weeks and at least 2 weeks following symptom resolution 2

Vaginal Candidiasis

  • Uncomplicated: Single 150 mg dose 1
  • Recurrent: 10-14 days induction with topical or oral azole, followed by 150 mg weekly for 6 months 1

Urinary Tract Candidiasis

  • Standard regimen: 200 mg (3 mg/kg) daily for 2 weeks for fluconazole-susceptible organisms 1
  • Urologic procedures: 400 mg (6 mg/kg) daily for several days before and after the procedure 1

Special Considerations

Candida Species Considerations

  • C. albicans: Generally susceptible to standard fluconazole doses 1
  • C. glabrata: Higher doses (800 mg daily) often recommended, but efficacy is lower (50%) 1, 3
  • C. krusei: Intrinsically resistant to fluconazole; alternative antifungals should be used 3
  • C. parapsilosis: Highly responsive to fluconazole (93% efficacy) 3

Patient-Specific Adjustments

Renal Impairment

  • Creatinine clearance >50 mL/min: 100% of recommended dose
  • Creatinine clearance ≤50 mL/min (no dialysis): 50% of recommended dose
  • Hemodialysis: 100% of recommended dose after each hemodialysis 2

Pediatric Dosing

  • Oropharyngeal candidiasis: 6 mg/kg on first day, then 3 mg/kg daily
  • Esophageal candidiasis: 6 mg/kg on first day, then 3 mg/kg daily (up to 12 mg/kg/day)
  • Systemic infections: 6-12 mg/kg/day 2

Treatment Duration

  • Candidemia: Minimum 2 weeks after blood culture clearance 1
  • Esophageal candidiasis: Minimum 3 weeks and at least 2 weeks after symptom resolution 2
  • Oropharyngeal candidiasis: Minimum 7-14 days 4

Common Pitfalls and Caveats

  • Fluconazole has poor activity against C. glabrata and no activity against C. krusei; identify species before committing to fluconazole therapy 1, 3
  • Fluconazole has significant drug interactions through cytochrome P450 inhibition; review patient's medication list before prescribing 1
  • For patients with recent azole exposure or critical illness, an echinocandin is preferred for initial therapy 1
  • Inadequate dosing is a common cause of treatment failure; use appropriate loading doses for invasive infections 1
  • CSF and vitreous penetration of fluconazole is excellent (>70% of serum concentration), making it suitable for CNS and ocular candidiasis 1

Fluconazole's excellent bioavailability (90%) means oral and intravenous doses are essentially equivalent, allowing for easy transition between routes of administration 1.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Fluconazole treatment of candidal infections caused by non-albicans Candida species.

European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 1996

Guideline

Oral Thrush Management

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.